RxDoctor Payments Data

Michele Fortune

Family · Vineland, NJNPI 1467957092

Payments from drug & device makers

$587in general payments, 2019–2025

Across 30 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$220
  • Viiv Healthcare Company$142
  • Shield Therapeutics Inc$76
  • Exact Sciences$28
  • Merck$26
  • Medtronic$21
  • plus $74 from 5 others

What the payments were for

  • Food & beverage$587100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$587 in reported general payments places this provider in the 65th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$814
Medicare patients
32
Services billed
42

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala159$626,905
DovatoDolutegravir Sodium/Lamivudine50$143,210
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf24$135,035
TivicayDolutegravir Sodium51$126,752
GenvoyaElviteg/Cob/Emtri/Tenof Alafen23$118,167
DescovyEmtricitabine/Tenofov Alafenam47$99,817
JanuviaSitagliptin Phosphate46$48,202
DelstrigoDoravirine/Lamivu/Tenofov Diso15$39,551
Darunavir34$38,651
OzempicSemaglutide34$36,587
EliquisApixaban34$25,323
JardianceEmpagliflozin20$22,028
XareltoRivaroxaban23$17,328
TradjentaLinagliptin12$17,168
Etravirine13$13,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$220$844,889229 claims
Viiv Healthcare CompanyDovato, Tivicay$142$269,962101 claims
MerckJanuvia, Delstrigo$26$87,75461 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$12$29,72669 claims
PfizerEliquis$16$25,32334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,692 family providers in New Jersey.

Other family in Vineland

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →